MYGN vs. CLDX, NTLA, QDEL, NEOG, LNTH, GPCR, AMRX, SUPN, AVDL, and HRMY
Should you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), QuidelOrtho (QDEL), Neogen (NEOG), Lantheus (LNTH), Structure Therapeutics (GPCR), Amneal Pharmaceuticals (AMRX), Supernus Pharmaceuticals (SUPN), Avadel Pharmaceuticals (AVDL), and Harmony Biosciences (HRMY). These companies are all part of the "medical" sector.
Celldex Therapeutics (NASDAQ:CLDX) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.
In the previous week, Myriad Genetics had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 2 mentions for Myriad Genetics and 0 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.36 beat Myriad Genetics' score of 0.00 indicating that Myriad Genetics is being referred to more favorably in the news media.
99.0% of Myriad Genetics shares are held by institutional investors. 3.7% of Celldex Therapeutics shares are held by company insiders. Comparatively, 2.0% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Myriad Genetics has a net margin of -34.96% compared to Myriad Genetics' net margin of -2,054.46%. Celldex Therapeutics' return on equity of -8.03% beat Myriad Genetics' return on equity.
Celldex Therapeutics presently has a consensus price target of $66.00, suggesting a potential upside of 81.82%. Myriad Genetics has a consensus price target of $23.17, suggesting a potential upside of 27.43%. Given Myriad Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Myriad Genetics.
Celldex Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500.
Celldex Therapeutics received 135 more outperform votes than Myriad Genetics when rated by MarketBeat users. Likewise, 74.84% of users gave Celldex Therapeutics an outperform vote while only 53.46% of users gave Myriad Genetics an outperform vote.
Celldex Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.
Summary
Celldex Therapeutics and Myriad Genetics tied by winning 9 of the 18 factors compared between the two stocks.
Get Myriad Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Myriad Genetics Competitors List
Related Companies and Tools
